Ratings by Oppenheimer (Matt Biegler)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 4/27/2026 | Relay Therapeutics | RLAY | Maintain | Outperform (N/A) |
|
Details | ||
| 4/13/2026 | Allogene | ALLO | Maintain | Outperform (N/A) |
|
Details | ||
| 3/27/2026 | OnKure Therapeutics Inc. | OKUR | Maintain | Outperform (N/A) |
|
Details | ||
| 3/27/2026 | Zentalis Pharmaceuticals | ZNTL | Maintain | Outperform (Outperform) |
|
Details | ||
| 3/16/2026 | Relay Therapeutics | RLAY | Maintain | Outperform (N/A) |
|
Details | ||
| 3/6/2026 | Day One Biopharmaceuticals | DAWN | Maintain | Perform (N/A) |
|
Details | ||
| 2/3/2026 | Tyra Biosciences | TYRA | Maintain | Outperform (N/A) |
|
Details | ||
| 1/26/2026 | Relay Therapeutics | RLAY | Upgrade | Outperform (Perform) |
7.43 (17.28) |
132.57% | Details | |
| 1/7/2026 | BridgeBio Oncology Therapeutics, In | BBOT | Maintain | Outperform (N/A) |
|
Details | ||
| 11/13/2025 | BridgeBio Oncology Therapeutics, In | BBOT | Maintain | Outperform (N/A) |
|
Details | ||
| 9/10/2025 | Tyra Biosciences | TYRA | Maintain | Outperform (N/A) |
|
Details | ||
| 9/4/2025 | BridgeBio Oncology Therapeutics, In | BBOT | New Coverage | Outperform (N/A) |
0.00 (7.56) |
0% | Details | |
| 8/1/2025 | Allogene | ALLO | Maintain | Outperform (N/A) |
|
Details | ||
| 5/14/2025 | Allogene | ALLO | Maintain | Outperform (N/A) |
|
Details | ||
| 3/11/2025 | OnKure Therapeutics Inc. | OKUR | Maintain | Outperform (N/A) |
|
Details | ||
| 1/29/2025 | Zentalis Pharmaceuticals | ZNTL | Maintain | Perform (N/A) |
|
Details | ||
| 11/8/2024 | Allogene | ALLO | Maintain | Outperform (N/A) |
|
Details | ||
| 10/10/2024 | OnKure Therapeutics Inc. | OKUR | New Coverage | Outperform (N/A) |
18.50 (4.44) |
-76% | Details | |
| 9/19/2024 | Tyra Biosciences | TYRA | Maintain | Outperform (N/A) |
|
Details | ||
| 9/16/2024 | Zentalis Pharmaceuticals | ZNTL | Maintain | Outperform (N/A) |
|
Details | ||
| 9/10/2024 | Relay Therapeutics | RLAY | Downgrade | Perform (Outperform) |
6.24 (7.43) |
19.07% | Details | |
| 8/8/2024 | Tyra Biosciences | TYRA | Maintain | Outperform (N/A) |
|
Details | ||
| 8/8/2024 | Allogene | ALLO | New Coverage | Outperform (N/A) |
2.47 (2.10) |
-14.98% | Details | |
| 8/7/2024 | Relay Therapeutics | RLAY | Maintain | Outperform (N/A) |
|
Details | ||
| 5/13/2024 | Tyra Biosciences | TYRA | Maintain | Outperform (N/A) |
|
Details | ||
| 5/6/2024 | Relay Therapeutics | RLAY | Maintain | Outperform (N/A) |
|
Details | ||
| 10/24/2023 | Elicio Therapeutics | ELTX | New Coverage | Perform (N/A) |
6.07 (4.14) |
-31.8% | Details | |
| 4/5/2023 | Relay Therapeutics | RLAY | Maintain | Outperform (N/A) |
|
Details | ||
| 3/6/2023 | Tyra Biosciences | TYRA | Maintain | Outperform (N/A) |
|
Details | ||
| 3/1/2023 | Tyra Biosciences | TYRA | Maintain | Outperform (N/A) |
|
Details | ||
| 2/3/2023 | Relay Therapeutics | RLAY | New Coverage | Outperform (N/A) |
21.68 (6.24) |
-71.22% | Details | |
| 2/3/2023 | Tyra Biosciences | TYRA | New Coverage | Outperform (N/A) |
13.20 (28.21) |
113.71% | Details | |
| 2/3/2023 | Day One Biopharmaceuticals | DAWN | New Coverage | Perform (N/A) |
21.53 (21.53) |
0% | Details | |
| 11/10/2022 | Zentalis Pharmaceuticals | ZNTL | Maintain | Outperform (N/A) |
|
Details | ||
| 8/10/2022 | Zentalis Pharmaceuticals | ZNTL | Maintain | Outperform (N/A) |
|
Details | ||
| 4/12/2022 | Zentalis Pharmaceuticals | ZNTL | Maintain | Outperform (N/A) |
|
Details | ||
| 12/17/2021 | Zentalis Pharmaceuticals | ZNTL | Maintain | Outperform (N/A) |
|
Details | ||
| 9/29/2021 | Zentalis Pharmaceuticals | ZNTL | New Coverage | Outperform (N/A) |
63.38 (3.67) |
-94.21% | Details |
